crenolanib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702581
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
crenolanib-resistant FLT3 mutants
Click the image above or here to open this pathway in the Pathway Browser

Crenolanib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Staudt et al, 2018; Larrosa-Garcia and Bauer, 2017). This pathway describes FLT3 mutants that are resistant to crenolanib-mediated inhibition.

Literature References
PubMed ID Title Journal Year
28576946 FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Larrosa-Garcia, M, Baer, MR

Mol. Cancer Ther. 2017
30651634 Targeting FLT3 mutations in AML: review of current knowledge and evidence

Daver, N, Schlenk, RF, Russell, NH, Levis, MJ

Leukemia 2019
30332834 Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

Staudt, D, Murray, HC, McLachlan, T, Alvaro, F, Enjeti, AK, Verrills, NM, Dun, MD

Int J Mol Sci 2018
Participants
Events
Participant Of
hasEvent
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!